Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function

Rondinelli, Maurizio; Rossi, Antônio; Gandolfi, Alessandra; Saponaro, Fabio; Bucciarelli, Loredana; Adda, Guido; Molinari, Chiara; Montefusco, Laura; Specchia, Claudia; Rossi, Maria Chiara; Scardapane, Marco; Arosio, Maura; Genovese, Stefano

doi:10.1016/j.clinthera.2016.11.001

Cited by 17 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Individuals that initiated liraglutide treatment in this setting were aged ~ 56 years, with advanced Type 2 diabetes (~ 9 years of disease), and in complex treatment regimens (35% receiving insulin). Participants had mean baseline HbA 1c of 68 mmol/mol (8.4%), in agreement with previous observational studies and randomized clinical trials (RCTs) . However, individuals were heavier (BMI 39.1 kg/m 2 ) than those in other epidemiological studies and RCTs (BMI 24–38.6 kg/m 2 ) .…”

Section: Discussionsupporting

confidence: 86%

“…At baseline, individuals presented elevated triglyceride and LDL, in the range of those observed in previous retrospective studies [22,23]. The study population was characterized by elevated BP (SBP 153 mmHg and DBP 86 mmHg) which, in the case of SBP, was higher than those in other observational studies [16,18,19,[22][23][24]. Taken together, participants initiated on liraglutide were obese and at advanced stages of the disease, with uncontrolled HbA 1c , lipid levels and BP.…”

Section: Discussionmentioning

confidence: 61%

“…We also analysed the temporary trend in well‐established disease variables over a 24‐month period. In this regard, it is important to highlight that most RCTs last 26 or 52 weeks, whereas real‐world studies usually analyse the change in clinical variables from baseline to 6‐ or 12‐month follow‐up, except for the study of Rondinelli and co‐workers in which liraglutide effects were analysed over 36 months . This implies that our study is one of the few reporting the evolution of clinical outcomes over a period of more than 12 months.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real‐world retrospective study conducted in Spain

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real‐world retrospective study conducted in Spain

et al. 2018

View full text Add to dashboard Cite

show abstract

“…These benefits together with weight loss implied a positive impact of beinaglutide on overall cardiovascular outcomes. However, this comprehensive beneficial efficacy was not unexpected, as indicated by previous studies of GLP‐1RAs .…”

Section: Discussionmentioning

confidence: 99%

Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study

Zhang¹,

Zhou

Li³

et al. 2019

Obesity Science & Practice

View full text Add to dashboard Cite

Summary Aims The purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA 1c ), blood pressure and lipid profiles in patients with type 2 diabetes mellitus (T2DM) in a real‐world setting in China. Materials and methods This was a multicentre, observational, retrospective, open‐label study conducted in China. Data were collected from T2DM patients who started treatment with beinaglutide between 2017 and 2018. Results A total of 314 patients were included in the study. After 3 months of treatment with beinaglutide, there were significant reductions in body weight (−10.05 kg [95% confidence interval −9.29 to −10.80]), HbA 1c (−2.87% [−2.62 to −3.11]), 2‐h postprandial plasma glucose (−5.46 mmol L −1 [−4.96 to −5.95]) and fasting plasma glucose (−3.04 mmol L −1 [−2.78 to −3.31]) (all p < 0.0001). In addition, 84.96% and 72.18% of the patients achieved weight loss of ≥5% and ≥10%, respectively. Subgroup analyses showed that weight loss was significantly greater in patients with ≥28 kg m −2 of baseline body mass index and 0.60 mg of beinaglutide doses ( p = 0.007 and p < 0.0001, respectively). HbA 1c reductions were significantly greater in patients with ≥9.0% baseline HbA 1c and in those administered 0.40–0.48 mg of beinaglutide doses (all p < 0.0001). Weight loss at 3 months was positively correlated with baseline BMI and the dose of beinaglutide. Positive determinants for HbA 1c reduction after 3 months were baseline HbA 1c and the dose of beinaglutide. Conclusions These observational results confirmed the benefits of beinaglutide in weight loss and glycaemic control and support the use of beinaglutide as an effective treatment for T2DM.

show abstract

“…Patients with DM have multiple systemic risk factors that likely contribute together to the endothelial phenotype observed, including differences in lipid profile. Prior studies have shown that administration of GLP‐1 agonists has an impact on lipid homeostasis 72, 73, 74, 75. Liraglutide administration appears to have beneficial effects on plasma lipids and lipoproteins, including a reduction in total cholesterol, triglycerides, and low‐density lipoprotein cholesterol, and an increase in high‐density lipoprotein cholesterol 76, 77, 78.…”

Section: Discussionmentioning

confidence: 99%

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus

Bretón‐Romero

Weisbrod

Feng

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundPrior studies have shown that nutrient excess induces endoplasmic reticulum (ER) stress in nonvascular tissues from patients with diabetes mellitus (DM). ER stress and the subsequent unfolded protein response may be protective, but sustained activation may drive vascular injury. Whether ER stress contributes to endothelial dysfunction in patients with DM remains unknown.Methods and ResultsTo characterize vascular ER stress, we isolated endothelial cells from 42 patients with DM and 37 subjects without DM. Endothelial cells from patients with DM displayed higher levels of ER stress markers compared with controls without DM. Both the early adaptive response, evidenced by higher phosphorylated protein kinase–like ER eukaryotic initiation factor‐2a kinase and inositol‐requiring ER‐to‐nucleus signaling protein 1 (P=0.02, P=0.007, respectively), and the chronic ER stress response evidenced by higher C/EBPα‐homologous protein (P=0.02), were activated in patients with DM. Higher inositol‐requiring ER‐to‐nucleus signaling protein 1 activation was associated with lower flow–mediated dilation, consistent with endothelial dysfunction (r=0.53, P=0.02). Acute treatment with liraglutide, a glucagon‐like peptide 1 receptor agonist, reduced p‐inositol‐requiring ER‐to‐nucleus signaling protein 1 (P=0.01), and the activation of its downstream target c‐jun N‐terminal kinase (P=0.025) in endothelial cells from patients with DM. Furthermore, liraglutide restored insulin‐stimulated endothelial nitric oxide synthase activation in patients with DM (P=0.019).ConclusionsIn summary, our data suggest that ER stress contributes to vascular insulin resistance and endothelial dysfunction in patients with DM. Further, we have demonstrated that liraglutide ameliorates ER stress, decreases c‐jun N‐terminal kinase activation and restores insulin‐mediated endothelial nitric oxide synthase activation in endothelial cells from patients with DM.

show abstract

Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function

Cited by 17 publications

References 26 publications

Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real‐world retrospective study conducted in Spain

Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real‐world retrospective study conducted in Spain

Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus

Contact Info

Product

Resources

About